JP2022522486A5 - - Google Patents

Info

Publication number
JP2022522486A5
JP2022522486A5 JP2021551785A JP2021551785A JP2022522486A5 JP 2022522486 A5 JP2022522486 A5 JP 2022522486A5 JP 2021551785 A JP2021551785 A JP 2021551785A JP 2021551785 A JP2021551785 A JP 2021551785A JP 2022522486 A5 JP2022522486 A5 JP 2022522486A5
Authority
JP
Japan
Prior art keywords
body weight
days
approximately
ring
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021551785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522486A (ja
JP7565292B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/076723 external-priority patent/WO2020177587A1/zh
Publication of JP2022522486A publication Critical patent/JP2022522486A/ja
Publication of JP2022522486A5 publication Critical patent/JP2022522486A5/ja
Application granted granted Critical
Publication of JP7565292B2 publication Critical patent/JP7565292B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021551785A 2019-03-01 2020-02-26 脂肪性肝疾患および/または脂肪性肝炎の処置方法 Active JP7565292B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/076688 2019-03-01
CN2019076688 2019-03-01
PCT/CN2020/076723 WO2020177587A1 (zh) 2019-03-01 2020-02-26 治疗脂肪性肝病和/或脂肪性肝炎的方法

Publications (3)

Publication Number Publication Date
JP2022522486A JP2022522486A (ja) 2022-04-19
JP2022522486A5 true JP2022522486A5 (cg-RX-API-DMAC7.html) 2023-03-06
JP7565292B2 JP7565292B2 (ja) 2024-10-10

Family

ID=72337009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021551785A Active JP7565292B2 (ja) 2019-03-01 2020-02-26 脂肪性肝疾患および/または脂肪性肝炎の処置方法

Country Status (11)

Country Link
US (1) US12485108B2 (cg-RX-API-DMAC7.html)
EP (1) EP3932404A4 (cg-RX-API-DMAC7.html)
JP (1) JP7565292B2 (cg-RX-API-DMAC7.html)
KR (1) KR102906316B1 (cg-RX-API-DMAC7.html)
CN (1) CN113490493B (cg-RX-API-DMAC7.html)
AU (1) AU2020230574B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017354A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132228A1 (cg-RX-API-DMAC7.html)
IL (1) IL285989B2 (cg-RX-API-DMAC7.html)
TW (1) TWI852999B (cg-RX-API-DMAC7.html)
WO (1) WO2020177587A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118772118A (zh) * 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
CN113135900B (zh) * 2021-03-12 2022-05-24 中山大学 吲哚嘧啶类化合物及其合成方法和应用
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
EP4434513A4 (en) * 2021-11-16 2025-11-19 Beijing Tide Pharmaceutical Co Ltd NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND ITS PREPARATION PROCESS
KR20250004665A (ko) * 2022-03-14 2025-01-08 퍼듀 리서치 파운데이션 비장 티로신 키나아제 억제제, 조성물 및 사용 방법
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
WO2025017500A1 (en) 2023-07-17 2025-01-23 Graviton Bioscience Bv Formulations of rock2 inhibitors for cns disorders
AU2024292342A1 (en) 2023-07-17 2026-02-26 Graviton Bioscience Bv Formulations and uses of rock2 inhibitors for als
CN117122602B (zh) * 2023-09-26 2026-03-20 赣南创新与转化医学研究院 化合物在制备治疗和/或预防脂肪肝病及相关疾病的药物中的用途
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040499A2 (en) * 2010-09-22 2012-03-29 Surface Logix, Inc. Metabolic inhibitors
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
EP3504204A4 (en) 2016-08-26 2020-05-27 Lycera Corporation INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
WO2019000683A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP7311228B2 (ja) * 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase

Similar Documents

Publication Publication Date Title
JP2022539329A5 (cg-RX-API-DMAC7.html)
ES2617628T5 (es) Régimen de dosificación para un agonista selectivo del receptor de S1P1
KR102906316B1 (ko) 지방간 질환 및/또는 지방간염의 치료 방법
WO2017146236A1 (ja) Axl阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
KR101640263B1 (ko) 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
CN119868365A (zh) 治疗特发性肺纤维化的方法
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
JP2018523689A5 (cg-RX-API-DMAC7.html)
JP2023505434A5 (cg-RX-API-DMAC7.html)
JP2024507414A5 (cg-RX-API-DMAC7.html)
JP2024524312A (ja) アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用
US20100222376A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
CN110087653A (zh) 用于治疗肺高血压的组合疗法
US20080214509A1 (en) Methods for enhancing the efficacy of vascular disrupting agents
JP2022531570A5 (cg-RX-API-DMAC7.html)
TW202304914A (zh) 經取代之四環羧酸、其類似物及使用其之方法
JP2022554330A5 (cg-RX-API-DMAC7.html)
JP2016503035A (ja) 肝疾患または肝障害の治療のための使用および方法
JP2023535035A5 (cg-RX-API-DMAC7.html)
US20090263334A1 (en) Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals
JP2022530890A5 (cg-RX-API-DMAC7.html)
JP2002097158A (ja) アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
CN120936376A (zh) 用于治疗与etbr激活相关的癌症的方法
WO2024018403A1 (en) Substituted imidazoamide compounds, and methods using same
KR20080007607A (ko) 심혈관 질환의 치료 및/또는 예방을 위한 라파마이신유도체의 용도